Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts

BACKGROUND: Bevacizumab is a monoclonal antibody against vascular endothelial growth factor. Severe pulmonary haemorrhage (PH) is a rare but serious potential adverse event associated with bevacizumab therapy for advanced non-squamous non-small-cell lung cancer (NSCLC). METHODS: A panel of expert on...

Descripción completa

Detalles Bibliográficos
Autores principales: Reck, M., Barlesi, F., Crinò, L., Henschke, C. I., Isla, D., Stiebeler, S., Spigel, D. R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2012
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335247/
https://www.ncbi.nlm.nih.gov/pubmed/22056855
http://dx.doi.org/10.1093/annonc/mdr463

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335247/
https://www.ncbi.nlm.nih.gov/pubmed/22056855
http://dx.doi.org/10.1093/annonc/mdr463

Ejemplares similares